Travere Therapeutics (TVTX) Revenue (2014 - 2026)
Travere Therapeutics' (TVTX) quarterly Revenue came in at $127.2 million in Q1 2026, up 55.63% YoY from $81.7 million in Q1 2025, and up 136.16% on a QoQ basis from -$351.7 million in Q4 2025.
Travere Therapeutics (TVTX) Revenue (2014 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 13 years of Revenue data on file, last reported at $127.2 million in Q1 2026.
- Quarterly Revenue rose 55.63% year-over-year to $127.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$70.1 million (down 125.62% YoY) and the FY2025 annual result came in at $9.3 million, down 96.01% from the prior year.
- Revenue advanced to $127.2 million in Q1 2026, from -$351.7 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $127.2 million in Q1 2026 to a low of -$351.7 million in Q4 2025.
- A 5-year average of $29.4 million and a median of $40.0 million in 2025 frame the typical range for Revenue.
- Annual changes were most pronounced in 2022 — Revenue soared 118.54% — and 2025, when it slumped 570.32%.
- Tracing TVTX's Revenue over 5 years: stood at $29.3 million in 2022, then jumped by 53.58% to $45.1 million in 2023, then surged by 65.98% to $74.8 million in 2024, then tumbled by 570.32% to -$351.7 million in 2025, then surged by 136.16% to $127.2 million in 2026.
- The last three Revenue figures came in at $127.2 million (Q1 2026), -$351.7 million (Q4 2025), and $40.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 169.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 169.58 Mn |
| Mar 31, 2026 | 127.20 Mn |
| Dec 31, 2025 | -351.74 Mn |
| Sep 30, 2025 | 40.00 Mn |
| Jun 30, 2025 | 114.45 Mn |
| Mar 31, 2025 | 81.73 Mn |
| Dec 31, 2024 | 74.79 Mn |
| Sep 30, 2024 | 62.90 Mn |
| Jun 30, 2024 | 54.12 Mn |
| Mar 31, 2024 | 41.37 Mn |
| Dec 31, 2023 | 45.06 Mn |
| Sep 30, 2023 | 37.10 Mn |
| Jun 30, 2023 | 32.20 Mn |
| Mar 31, 2023 | 30.89 Mn |
| Dec 31, 2022 | 29.34 Mn |
| Sep 30, 2022 | 28.08 Mn |
| Jun 30, 2022 | 28.63 Mn |
| Mar 31, 2022 | 23.41 Mn |
| Dec 31, 2021 | -158.24 Mn |
| Sep 30, 2021 | 68.22 Mn |